標(biāo)題: Titlebook: Direct Oral Anticoagulants; From Pharmacology to Riccardo Proietti,Ahmed AlTurki,T. Jared Bunch Book 2021 Springer Nature Switzerland AG 20 [打印本頁] 作者: FAD 時(shí)間: 2025-3-21 16:05
書目名稱Direct Oral Anticoagulants影響因子(影響力)
作者: Itinerant 時(shí)間: 2025-3-21 21:12 作者: modish 時(shí)間: 2025-3-22 01:43
Pharmacokinetics and Pharmacodynamics of DOAC, dabigatran (a reversible direct thrombin inhibitor) and the direct factor Xa inhibitors rivaroxaban, apixaban, and edoxaban offer fixed dosing, more predictable pharmacokinetics and fewer interactions with drugs and food than warfarin. Results from clinical trials demonstrated an improved benefit-r作者: 先鋒派 時(shí)間: 2025-3-22 05:32 作者: Urea508 時(shí)間: 2025-3-22 10:47 作者: 粗語 時(shí)間: 2025-3-22 13:59
Risk Stratification For and Use of DOAC Therapies for Stroke Prevention in Patient with Atrial Fibrant agents play a key role in preventing this complication. Through years, several risk stratification algorithms have been investigated, while others are still object of debate. According to current guidelines, CHA2DS2VASc score and HAS-BLED score are the ones suggested for stroke and bleeding risk作者: 粗語 時(shí)間: 2025-3-22 20:39
Use of DOAC in Patients with Kidney Disease,morrhagic events are increased in patients with kidney disease. Oral anticoagulation therapy, nowadays preferably with direct oral anticoagulants (DOACs), represents the cornerstone for ischemic stroke prevention in high-risk patients. However, all four available DOACs (dabigatran, apixaban, rivarox作者: falsehood 時(shí)間: 2025-3-23 00:26 作者: echnic 時(shí)間: 2025-3-23 03:09
,The “Obesity Paradox” and the Use of NOAC,ovascular (CV) risk, more and more evidences suggest a favorable prognosis in obese subjects with cardiovascular disease (CVD), a phenomenon known as “obesity paradox.” Obesity paradox has been demonstrated in various CVD including atrial fibrillation (AF) and venous thromboembolism (VTE) for which 作者: 反抗者 時(shí)間: 2025-3-23 05:41 作者: 支形吊燈 時(shí)間: 2025-3-23 10:43
DOACs and Dementia in Patients with Atrial Fibrillation,ciation likely extends beyond an epiphenomenon due to aging as large observational studies have shown that the youngest groups studied who developed AF had the higher risks for cognitive impairment. AF has been identified as an independent risk factor for dementia, including Alzheimer’s, vascular, a作者: Bucket 時(shí)間: 2025-3-23 15:55
Non-vitamin K Antagonists and Cardiac Implantable Electronic Devices,void the potential significant adverse events of pocket hematoma and pocket infection. Key to this management is the decision to continue or interrupt oral anticoagulation. Continued vitamin K antagonist therapy has been shown to be superior to a bridging anticoagulation strategy. In those receiving作者: 四海為家的人 時(shí)間: 2025-3-23 20:09 作者: –吃 時(shí)間: 2025-3-24 01:10
DOAC Therapy in Patients Post Left Atrial Appendage Occlusion or Isolation,tations with contemporary anticoagulation therapies have provided a very attractive substrate for the development of alternative approaches to reduce stroke rates in patients with AF. When an intracardiac source of stroke is identified in patients with atrial fibrillation, the left atrial appendage 作者: MOTTO 時(shí)間: 2025-3-24 05:19 作者: OVER 時(shí)間: 2025-3-24 07:06
Use of Direct Oral Anticoagulants After Percutaneous Coronary Intervention,omboembolic complications, such as stroke and systemic embolic events. Unless contraindicated, current guidelines suggest that direct oral anticoagulants (DOAC) should be preferred over vitamin K antagonists. Of note, nearly 30% of AF patients also present with concomitant coronary artery disease re作者: 來就得意 時(shí)間: 2025-3-24 11:10 作者: 新義 時(shí)間: 2025-3-24 18:33
Sports and Nationalism in Latin / o Americaa damaged vessel and to restore vascular integrity. By taking place on the surface of activated platelets, aim of coagulation is to generate fibrin meshes that stabilize the platelet plug and thus stop blood loss. Under normal conditions, anticoagulant mechanisms ensure careful control of coagulatio作者: 斗爭(zhēng) 時(shí)間: 2025-3-24 19:36 作者: DECRY 時(shí)間: 2025-3-25 01:14 作者: 粉筆 時(shí)間: 2025-3-25 05:24
https://doi.org/10.1007/978-981-32-9127-0thromboprophylaxis in patients with non-valvular atrial fibrillation (NVAF) and for the treatment and prevention of venous thromboembolism (VTE). In patients with multiple conditions, as in particular NVAF ones or with cancer, the contemporary administration of several drugs can cause relevant drug–作者: mighty 時(shí)間: 2025-3-25 08:35
The Community Street Soccer Programr Xa inhibitors (rivaroxaban, apixaban, edoxaban, betrixaban). They have largely replaced vitamin K anticoagulants (VKAs) in clinical practice. Their overall safety profile concerning bleeding appears to be at least equivalent, if not superior, to VKAs. However, the lack of a specific reversal agent作者: SEEK 時(shí)間: 2025-3-25 12:01
https://doi.org/10.1007/978-1-4614-5996-5ant agents play a key role in preventing this complication. Through years, several risk stratification algorithms have been investigated, while others are still object of debate. According to current guidelines, CHA2DS2VASc score and HAS-BLED score are the ones suggested for stroke and bleeding risk作者: Reservation 時(shí)間: 2025-3-25 16:29
William J. Moreau,Dustin Nabhanmorrhagic events are increased in patients with kidney disease. Oral anticoagulation therapy, nowadays preferably with direct oral anticoagulants (DOACs), represents the cornerstone for ischemic stroke prevention in high-risk patients. However, all four available DOACs (dabigatran, apixaban, rivarox作者: extemporaneous 時(shí)間: 2025-3-25 22:12 作者: acolyte 時(shí)間: 2025-3-26 03:46
Brenden J. Balcik,Aaron J. Monseauovascular (CV) risk, more and more evidences suggest a favorable prognosis in obese subjects with cardiovascular disease (CVD), a phenomenon known as “obesity paradox.” Obesity paradox has been demonstrated in various CVD including atrial fibrillation (AF) and venous thromboembolism (VTE) for which 作者: bronchodilator 時(shí)間: 2025-3-26 06:57
https://doi.org/10.1007/978-3-030-36790-9thromboembolism is a leading cause of mortality, especially in patients undergoing chemotherapy. The anticoagulant strategy to be administered in these cases is particularly difficult to choose due to an altered state of coagulation that makes the balance between hypercoagulation and bleeding risk i作者: 神化怪物 時(shí)間: 2025-3-26 12:02 作者: 思考才皺眉 時(shí)間: 2025-3-26 14:24 作者: companion 時(shí)間: 2025-3-26 18:58 作者: glisten 時(shí)間: 2025-3-27 00:58 作者: 勤勉 時(shí)間: 2025-3-27 02:08 作者: 伙伴 時(shí)間: 2025-3-27 08:31
Sportswomen’s Apparel Around the Worldomboembolic complications, such as stroke and systemic embolic events. Unless contraindicated, current guidelines suggest that direct oral anticoagulants (DOAC) should be preferred over vitamin K antagonists. Of note, nearly 30% of AF patients also present with concomitant coronary artery disease re作者: Omnipotent 時(shí)間: 2025-3-27 11:09 作者: recession 時(shí)間: 2025-3-27 13:43 作者: 宣誓書 時(shí)間: 2025-3-27 18:52
978-3-030-74464-9Springer Nature Switzerland AG 2021作者: 關(guān)節(jié)炎 時(shí)間: 2025-3-27 22:44
Riccardo Proietti,Ahmed AlTurki,T. Jared BunchAssesses important drug-drug interactions in patients with chronic kidney disease and cancer.Provides concise easy to digest information on the use of DOACs in perioperative management.Details the app作者: Breach 時(shí)間: 2025-3-28 04:13 作者: Eclampsia 時(shí)間: 2025-3-28 10:02 作者: carotenoids 時(shí)間: 2025-3-28 13:33
New Directions in Latino American Cultures. Observational data has suggested that DOACs are noninferior to warfarin for treatment of left ventricular thrombus and stroke prevention in rheumatic mitral valve disease. Large, randomized trials are clearly needed to inform anticoagulation selection in these populations. Two areas in which data 作者: MEAN 時(shí)間: 2025-3-28 15:44 作者: 滴注 時(shí)間: 2025-3-28 19:44
The Community Street Soccer Programted patients who present with life-threatening bleeding or with indication for emergent surgery. We will also review the mechanism of action and data supporting the use of specific reversal agents, nonspecific pro-hemostatic therapies including prothrombin complex concentrate, and future research av作者: Lyme-disease 時(shí)間: 2025-3-29 00:18 作者: 投射 時(shí)間: 2025-3-29 03:34
William J. Moreau,Dustin Nabhanarin, showing a better safety profile. Patients with atrial fibrillation on dialysis have been traditionally treated with warfarin, but its effectiveness for stroke prevention in this population is questionable. Some retrospective studies showed promising results with apixaban, but years will be nee作者: Entropion 時(shí)間: 2025-3-29 07:57 作者: 寬大 時(shí)間: 2025-3-29 12:47
Katherine M. Edenfield,Jocelyn R. Gravleerapeutic range is associated with less dementia. This potentially reflects a reduction in the risk of micro thromboembolisms and microvascular bleeds, respectively. Direct oral anticoagulants (DOACs) have been shown to be superior or noninferior to warfarin in reducing the risk of thromboembolism an作者: 小木槌 時(shí)間: 2025-3-29 16:48
Andrew Pasternak,Brian J. Krabaking in all surgeries. Therefore, NOAC interruption involves timing the cessation and reinitiation of the drug based on the predicted clearance, which takes renal function into account. In patients with normal renal function undergoing a low bleeding risk procedure, the usual practice is to discontin作者: Mercurial 時(shí)間: 2025-3-29 20:33
Anna L. Waterbrook,Moira Davenport low overall risk who undergo ablation but the optimal anticoagulation strategy in patients post AF ablation has not been determined. An ongoing trial will evaluate whether cessation of DOAC is safe post ablation.作者: antipsychotic 時(shí)間: 2025-3-30 02:11 作者: 影響 時(shí)間: 2025-3-30 07:30
Sportswomen’s Apparel Around the Worldntiplatelet therapy aiming to achieve the best balance between bleeding and ischemic risk. However, in the DOAC era, the optimal management of AF patients requiring PCI is still debated, and ongoing studies and meta-analysis will probably change the landscape in the near future. The aim of this chap作者: cardiac-arrest 時(shí)間: 2025-3-30 09:14 作者: 細(xì)菌等 時(shí)間: 2025-3-30 14:09 作者: 媽媽不開心 時(shí)間: 2025-3-30 17:42 作者: 同步左右 時(shí)間: 2025-3-30 22:28 作者: 愉快嗎 時(shí)間: 2025-3-31 01:18
Use of DOAC in Patients with Kidney Disease,arin, showing a better safety profile. Patients with atrial fibrillation on dialysis have been traditionally treated with warfarin, but its effectiveness for stroke prevention in this population is questionable. Some retrospective studies showed promising results with apixaban, but years will be nee作者: Foregery 時(shí)間: 2025-3-31 08:26
Direct Oral Anticoagulation in Cancer Patients,ticoagulants may be as effective as vitamin K antagonists and low molecular weight heparins for the prevention of stroke and systemic embolism in patients with atrial fibrillation and cancer, and more interestingly, some randomized clinical trials are already available to compare direct oral anticoa
